Survodutide FAQ: common questions answered
A weekly dual-hormone injection with phase 3 weight-loss data and frequent stomach side effects.
Also called: BI 456906, BI456906, Survo.
GLP-1 / glucagon dual agonists · GLP-1 and glucagon receptor dual agonist.
- Is Survodutide FDA-approved? No FDA approval or dosing label found. FDA warns against research-labeled versions; “research use only” does not authorize human sale.
- How do people take it? Under the skin, once weekly. Source: reported by users, not an established dose.
- What's the difference between Survodutide and Tirzepatide? Survodutide: a weekly dual-hormone injection with phase 3 weight-loss data and frequent stomach side effects. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: people seek appetite control, energy or a broken weight-loss stall.
- Can I take it with Tirzepatide? People seek appetite control, energy or a broken weight-loss stall. Overlapping GLP-1 effects; combination doses and safety are not established. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). S0 applies to investigational substances without any governmental human-use approval.
- How long does a mixed vial last? No validated home-mixed stability or beyond-use time was found.
Related to Survodutide
- Mazdutide: A weekly dual-hormone injection approved in China, with phase 3 weight-loss results.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, Therapeutic Goods Administration · Therapeutic Goods Administration · 2026
- WEGOVY- semaglutide injection, solution WEGOVY- semaglutide tablet, DailyMed · DailyMed · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society., Mozaffarian D et al. · The American journal of clinical nutrition · 2025
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Drug Product Database: Access the database, Health Canada · Health Canada
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.